Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 18, 2021updated 25 Oct 2021 1:57pm

PoNS device from Helius Medical gets US FDA breakthrough status

The PoNS device is authorised and indicated in the US for patients with prescription only.

The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Helius Medical Technologies’ Portable Neuromodulation Stimulator (PoNS) device.

The designation allows the non-surgical device to be used as a temporary treatment for dynamic gait and balance deficits after a stroke as an adjunct to a therapeutic exercise programme in patients aged 22 years and above.

It delivers electrical stimulation to the tongue surface to provide treatment of gait deficit.

The device is commercially available in Canada for use as a short-term treatment (14 weeks) of gait deficiency due to mild-to-moderate symptoms from traumatic brain injury in conjunction with physical therapy.

In the US, it is authorised and indicated for patients with prescription only.

Helius Medical Technologies CEO Dane Andreeff said: “Strokes are a large and growing cause of long-term disability in the United States. An estimated seven million Americans are living with stroke-related complications, and more than 80% of stroke survivors are estimated to develop gait impairment.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

“Obtaining Breakthrough Designation represents an important milestone in our path to providing this underserved patient population with a non-drug, non-implantable treatment option that has the potential to significantly improve their gait and balance, their ability to walk and perform daily tasks.

“We look forward to building on this achievement by utilising the Breakthrough Devices Program to facilitate our pursuit of US regulatory clearance for treatment of stroke-induced symptoms in close collaboration with the FDA.”

Currently, the device is an investigational medical device in Australia and is under premarket review by the Australia Therapeutic Goods Administration.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy